Abstract:Hemoglobinopathies are among the most frequent monogenic disorders, with the worldwide incidence of carriers being around 7%. b-Thalassemia is very common in many areas of the Middle East and Southeastern Asia. The cost of providing lifelong medical care to the patients with thalassemia according to the standards adopted in the developed countries is extremely high. The burden of thalassemia imposed in the health systems of the developing countries is unbearable, especially as these countries suffer from many other significant public health problems like tuberculosis, HIV, and malaria. Therefore, the fact that the patients with thalassemia in developing countries are undertreated and the disease has been largely ignored by individual governments and local health authorities comes as no surprise. The need for therapeutic interventions alternative to chronic blood transfusion and iron chelation therapy for these patients is urgent. The article by Ansari et al underlines these issues. The trial presented shows the weaknesses of the health care system of developing countries and the struggle of the medical professionals to help their patients under adverse conditions. Few reports on the use of hemoglobin F-augmenting therapies in thalassemia have been published in the last few years. The efficacy of hydroxyurea (HU) in thalassemia intermedia has been documented, while results on its use in thalassemia major have been controversial. HU, an S-phase–specific and non–DNAhypomethylating chemotherapeutic agent, promotes fetal hemoglobin (HbF) production via reactivation of g-globin genes as a result of molecular mechanisms that are not yet fully elucidated. Erythroid cultures from different thalassemia patients in the presence of HU showed variable results, ranging from significant increases in both the number of HbF cells and the HbF content per cell to minimal effect. This variation in response to HU may be due to different genetic factors. In a recent study involving Iranian patients with thalassemia, the response to HU was found to be related to the haplotype of the b-globin gene locus, and more precisely to the type of the b-globin gene mutations and to the XmnI polymorphism. Of note is that in this study, homozygous patients for IVSI-5 (G-C), like the majority of the patients presented by Ansari et al, had a moderate response to the treatment with HU. A similar study from India suggested that the coexistence of deletion on the a-globin gene may positively affect the response to HU. The study by Ansari et al has some weaknesses, with the main being not standard transfusion criteria for the patients throughout their lifetime. It showed an amelioration of symptoms for the patients treated with HU, which was overall modest. Both the clinical status and the hematologic parameters improved in many patients, but they were still significantly inferior what would have been considered optimal in more developed countries. Nevertheless, as appropriate therapy cannot be introduced, this approach may actually be the best available therapeutic strategy for these patients.

Treatment of thalassemia with hydroxyurea: an indispensable alternative therapy.

Self-reported psychosocial needs and health-related quality of life of colorectal cancer survivors.

Evaluation of the spectral transmittance of UV-absorbing disposable contact lenses.

Association Between Neurological Status and Outcomes in Cardiac Arrest Patients Undergoing PCI in Contemporary Practice: Insights From BMC2

Identification, cDNA Cloning, and Gene Expression of Soluble Starch Synthase in Rice (Oryza sativa L.) Immature Seeds

A Comparison of Prognostic Factors in a Large Cohort of In-Hospital and Out-of-Hospital Cardiac Arrest Patients

Factors affecting neurological outcomes of patients with sudden cardiac arrest in the emergency department

Self-reported cognitive function and its relationship with self-reported health, psychological distress, and life satisfaction among cardiac arrest survivors - a nationwide register study

Long-term outcome and predictors of neurological recovery in cervical spinal cord injury: a population-based cohort study

Performance of the ERC/ESICM-recommendations for neuroprognostication after cardiac arrest: insights from a prospective multicenter cohort

Inactivation of sodium channels: second order kinetics in myelinated nerve

Neurophysiology State Dynamics Underlying Acute Neurological Recovery After Cardiac Arrest

Survival and Neurobehavioral Outcomes Following Out-of-Hospital Cardiac Arrest in Pediatric Patients with Pre-Existing Morbidity: An Analysis of the THAPCA Out-of-Hospital Arrest Data

Association of EEG Characteristics with Outcomes Following Pediatric ICU Cardiac Arrest: A Secondary Analysis of the ICU-RESUScitation Trial

Cardiac Arrest Survival Postresuscitation In-Hospital (CASPRI) Score Predicts Neurological Favorable Survival in Emergency Department Cardiac Arrest

Development of prognostic models for predicting 90-day neurological function and mortality after cardiac arrest

Aetiology and predictors of outcome in non-shockable in-hospital cardiac arrest: A retrospective cohort study from the Swedish Registry for Cardiopulmonary Resuscitation

Survivorship After Neurocritical Care: A Scoping Review of Outcomes Beyond Physical Status

Comorbidities prior to out-of-hospital cardiac arrest and diagnoses at discharge among survivors

Predictors of survival and neurologic outcome for adults with extracorporeal cardiopulmonary resuscitation: A systemic review and meta-analysis.

Neurobehavioral recovery in patients who emerged from prolonged disorder of consciousness: a retrospective study